Oncotelic Therapeutics, Inc. (OTLC)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.32 Million | -1.45 Million | -4.43 Million | -2.81 Million | -2.28 Million | -2.84 Million |
| Net Income | -7.9 Million | 4.67 Million | -10.51 Million | -9.97 Million | -6.63 Million | -2.73 Million |
| Depreciation & Amortization | 301.91 Thousand | 12.84 Thousand | 61.51 Thousand | 364.21 Thousand | 60.65 Thousand | 2000.00 |
| Deferred income taxes | - | - | 1.55 Million | 45.05 Thousand | 1.57 Million | - |
| Stock-based compensation | - | 902.14 Thousand | 763.31 Thousand | 2.14 Million | 340.67 Thousand | 744 Thousand |
| Change in working capital | -86.32 Thousand | 799.77 Thousand | 332.75 Thousand | 540.19 Thousand | 1.09 Million | -603 Thousand |
| Other non-cash items | 6.66 Million | -7.84 Million | 3.37 Million | 4.06 Million | 1.28 Million | -250 Thousand |
| Investing Cash Flow | - | - | - | - | 189.28 Thousand | - |
| Investments in PPE | -3.00 | - | - | - | - | - |
| Acquisitions | - | - | - | - | 189.28 Thousand | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | 189.28 Thousand | - |
| Financing Cash Flow | 1.25 Million | 1.12 Million | 4.52 Million | 3.22 Million | 2.17 Million | 2.35 Million |
| Debt repayment | -1.41 Million | -966.42 Thousand | -407.5 Thousand | -50 Thousand | -2.08 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -125 Thousand | - | - | - | - | - |
| Common Stock Issuance | - | 158.82 Thousand | 1.96 Million | 2.92 Million | 83 Thousand | 2.35 Million |
| Other Financing Activities | -35 Thousand | 1.93 Million | 2.97 Million | 345 Thousand | 4.17 Million | 240 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -45.93 Thousand | 802.96 Thousand | 249.66 Thousand | 470.77 Thousand | 1.17 Million | -599 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -40.39 Thousand | -3186.00 | 83.09 Thousand | 69.41 Thousand | -78.55 Thousand | -4000.00 |
| Cash at beginning of period | 261.45 Thousand | 588.76 Thousand | 494.01 Thousand | 81.96 Thousand | 2498.00 | 1.11 Million |
| Cash at end of period | 190.4 Thousand | 261.45 Thousand | 588.76 Thousand | 494.01 Thousand | 81.96 Thousand | 629 Thousand |
| Capital Expenditure | -3.00 | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -71.04 Thousand | -327.31 Thousand | 94.75 Thousand | 412.05 Thousand | 79.46 Thousand | -486 Thousand |
| Free Cash Flow | -1.32 Million | -1.45 Million | -4.43 Million | -2.81 Million | -2.28 Million | -2.84 Million |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -408.67 Thousand | -735.98 Thousand | -7.9 Million | 41.06 Thousand | -6.85 Million | -606.04 Thousand |
| Depreciation & Amortization | - | - | - | - | - | 166.43 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 119.96 Thousand | -354.15 Thousand | -86.32 Thousand | 173.87 Thousand | -74.74 Thousand | 168.69 Thousand |
| Other non-cash items | -43.94 Thousand | 717.52 Thousand | 6.66 Million | -463.78 Thousand | 6.47 Million | 19.89 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 250 Thousand | 275 Thousand | 1.25 Million | 335 Thousand | 440 Thousand | 200 Thousand |
| Debt repayment | -250 Thousand | -435 Thousand | -1.41 Million | -335 Thousand | -440 Thousand | -200 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -125 Thousand | -125 Thousand | -50 Thousand | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 250 Thousand | -35 Thousand | -35 Thousand | 720 Thousand | 880 Thousand | 400 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 101.23 Thousand | -353.53 Thousand | -45.93 Thousand | 175.64 Thousand | -17.3 Thousand | 149.25 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 18.73 Thousand | -624.00 | -40.39 Thousand | -1768.00 | -57.44 Thousand | 19.44 Thousand |
| Cash at beginning of period | 190.4 Thousand | 288.02 Thousand | 261.45 Thousand | 201.87 Thousand | 210.43 Thousand | 261.45 Thousand |
| Cash at end of period | 208.98 Thousand | 190.4 Thousand | 190.4 Thousand | 288.02 Thousand | 201.87 Thousand | 210.43 Thousand |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 18.58 Thousand | -97.61 Thousand | -71.04 Thousand | 86.15 Thousand | -8563.00 | -51.01 Thousand |
| Free Cash Flow | -231.41 Thousand | -372.61 Thousand | -1.32 Million | -248.85 Thousand | -448.56 Thousand | -251.01 Thousand |
CLX
603228
4082
3823
ALDX
BYAGF